Register
Login:
Share:
Email Facebook Twitter

Finance & Stock Market News


Antisoma's executives leave after drug setbacks

Mon, 28th Feb 2011 16:17


LONDON, Feb 28 (Reuters) - The top management of Antisoma stepped down on
Monday as the British cancer specialist cut its operations following the failure of its two leading drug candidates.

The company's leukaemia drug candidate AS1413 failed in a final-stage trial in January, delivering a second blow after the failure of a lung cancer drug, its biggest hope, in March 2010. [ID:nLDE70U090}

Chief Executive Glyn Edwards and finance director Eric Dodd had both resigned, the company said, although Dodd will continue to advises the firm on strategic options, which includes a sale of the company.

Shares in Antisoma, once one of Britain's brightest biotech hopes, were valued at more than 200 pence in March 2000 when the sector was riding high.

The shares were trading at 3 pence at 1554 GMT.

(Reporting by Paul Sandle) Keywords: ANTISOMA/

(paul.sandle@reuters.com; +44 20 7542-6843; Reuters Messaging: paul.sandle.reuters.com@reuters.net)

COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.


Related Shares: Antisoma (ASM).


Next Article: Greek Coke bottler sold 300 mln eur bond to repay debt

Back to Finance News


Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.